sulfasalazine has been researched along with Glial Cell Tumors in 21 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas." | 9.14 | Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. ( Albert, A; Artesi, M; Bours, V; Bredel, M; Califice, S; Deprez, M; Martin, DH; Nguyen-Khac, MT; Robe, PA; Vanbelle, S, 2009) |
| " A total of twenty patients with progressive malignant glioma despite surgery, radiation therapy and a first line of chemotherapy will be recruited and assigned to four dosage regimen of Sulfasalazine." | 9.12 | A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. ( Albert, A; Bours, V; Chariot, A; Deprez, M; Martin, D; Robe, PA, 2006) |
| "Autocrine and paracrine factors, including glutamate and epidermal growth factor (EGF), are potent inducers of brain tumor cell invasion, a pathological hallmark of malignant gliomas." | 7.88 | Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling. ( Akashi, K; Baba, E; Hirata, Y; Kamenori, S; Mitsuishi, Y; Nagano, O; Okazaki, S; Sampetrean, O; Saya, H; Shintani, S; Suina, K; Takahashi, F; Takahashi, K; Tsuchihashi, K; Yamasaki, J, 2018) |
| " Glioma cells may synthetize the antioxidant glutathione by importing cystine through a cystine/glutamate antiporter, which is inhibited by sulfasalazine (SAS)." | 7.85 | Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells. ( Castilho, RF; de Melo, DR; Facchini, G; Ferreira, CV; Ignarro, RS; Pelizzaro-Rocha, KJ; Rogerio, F, 2017) |
| " Food and Drug Administration and EMA-approved xCT inhibitor, sulfasalazine (SAS) in gliomas." | 7.83 | Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. ( Buchfelder, M; Dörfler, A; Engelhorn, T; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Klucken, J; Minakaki, G; Rauh, M; Savaskan, N; Sehm, T, 2016) |
| " Celastrol, isolated from a Chinese medicinal herb, is a novel heat shock protein 90 (Hsp90) inhibitor with potent anticancer activity against glioma in vitro and in vivo." | 7.76 | Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines. ( Alvarado, O; Blower, PE; Gout, PW; Huang, Y; Pham, AN; Ravula, R, 2010) |
| "The efficacy of HSV-TK/ganciclovir-based gene therapy on malignant gliomas largely relies on the amplitude of the bystander effect." | 7.74 | Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. ( Bours, V; Ernst-Gengoux, P; Jolois, O; Lambert, F; Lechanteur, C; Nguyen-Khac, MT; Robe, PA; Rogister, B, 2007) |
| "Sulfasalazine (SAS) is a classic inhibitor of NF-κB." | 5.42 | p62 participates in the inhibition of NF-κB signaling and apoptosis induced by sulfasalazine in human glioma U251 cells. ( Kang, J; Li, X; Li, Y; Liu, F; Su, J; Sun, L; Xia, M; Xu, Y, 2015) |
| "Celecoxib has been utilized with success in the treatment of several types of cancer, including gliomas." | 5.42 | Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine. ( Winfield, LL; Yerokun, T, 2015) |
| "Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas." | 5.14 | Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. ( Albert, A; Artesi, M; Bours, V; Bredel, M; Califice, S; Deprez, M; Martin, DH; Nguyen-Khac, MT; Robe, PA; Vanbelle, S, 2009) |
| " A total of twenty patients with progressive malignant glioma despite surgery, radiation therapy and a first line of chemotherapy will be recruited and assigned to four dosage regimen of Sulfasalazine." | 5.12 | A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. ( Albert, A; Bours, V; Chariot, A; Deprez, M; Martin, D; Robe, PA, 2006) |
| "Autocrine and paracrine factors, including glutamate and epidermal growth factor (EGF), are potent inducers of brain tumor cell invasion, a pathological hallmark of malignant gliomas." | 3.88 | Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling. ( Akashi, K; Baba, E; Hirata, Y; Kamenori, S; Mitsuishi, Y; Nagano, O; Okazaki, S; Sampetrean, O; Saya, H; Shintani, S; Suina, K; Takahashi, F; Takahashi, K; Tsuchihashi, K; Yamasaki, J, 2018) |
| " Glioma cells may synthetize the antioxidant glutathione by importing cystine through a cystine/glutamate antiporter, which is inhibited by sulfasalazine (SAS)." | 3.85 | Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells. ( Castilho, RF; de Melo, DR; Facchini, G; Ferreira, CV; Ignarro, RS; Pelizzaro-Rocha, KJ; Rogerio, F, 2017) |
| " Food and Drug Administration and EMA-approved xCT inhibitor, sulfasalazine (SAS) in gliomas." | 3.83 | Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. ( Buchfelder, M; Dörfler, A; Engelhorn, T; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Klucken, J; Minakaki, G; Rauh, M; Savaskan, N; Sehm, T, 2016) |
| " Celastrol, isolated from a Chinese medicinal herb, is a novel heat shock protein 90 (Hsp90) inhibitor with potent anticancer activity against glioma in vitro and in vivo." | 3.76 | Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines. ( Alvarado, O; Blower, PE; Gout, PW; Huang, Y; Pham, AN; Ravula, R, 2010) |
| " Sulfasalazine which is used clinically to treat Crohn's disease has emerged as a potential inhibitor of NF-kappaB and has shown promising results in two pre-clinical studies to target primary brain tumors, gliomas." | 3.75 | Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. ( Chung, WJ; Sontheimer, H, 2009) |
| "The efficacy of HSV-TK/ganciclovir-based gene therapy on malignant gliomas largely relies on the amplitude of the bystander effect." | 3.74 | Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. ( Bours, V; Ernst-Gengoux, P; Jolois, O; Lambert, F; Lechanteur, C; Nguyen-Khac, MT; Robe, PA; Rogister, B, 2007) |
| "Gliomas are primary brain tumors with still poor prognosis for the patients despite a combination of cytoreduction via surgery followed by a radio-chemotherapy." | 1.62 | Chemical hybridization of sulfasalazine and dihydroartemisinin promotes brain tumor cell death. ( Ackermann, A; Buchfelder, M; Çapcı, A; Savaskan, N; Tsogoeva, SB, 2021) |
| "Sulfasalazine (SAS) is a classic inhibitor of NF-κB." | 1.42 | p62 participates in the inhibition of NF-κB signaling and apoptosis induced by sulfasalazine in human glioma U251 cells. ( Kang, J; Li, X; Li, Y; Liu, F; Su, J; Sun, L; Xia, M; Xu, Y, 2015) |
| "Celecoxib has been utilized with success in the treatment of several types of cancer, including gliomas." | 1.42 | Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine. ( Winfield, LL; Yerokun, T, 2015) |
| "Control of seizures in patients with gliomas is an essential component of clinical management; therefore, understanding the origin of seizures is vital." | 1.38 | Human glioma cells induce hyperexcitability in cortical networks. ( Buckingham, SC; Campbell, SL; Sontheimer, H, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Ackermann, A | 1 |
| Çapcı, A | 1 |
| Buchfelder, M | 2 |
| Tsogoeva, SB | 1 |
| Savaskan, N | 2 |
| Cong, Z | 1 |
| Yuan, F | 1 |
| Wang, H | 1 |
| Cai, X | 1 |
| Zhu, J | 1 |
| Tang, T | 1 |
| Zhang, L | 1 |
| Han, Y | 1 |
| Ma, C | 1 |
| Haryu, S | 1 |
| Saito, R | 1 |
| Jia, W | 1 |
| Shoji, T | 1 |
| Mano, Y | 1 |
| Sato, A | 1 |
| Kanamori, M | 1 |
| Sonoda, Y | 1 |
| Sampetrean, O | 3 |
| Saya, H | 3 |
| Tominaga, T | 1 |
| Suina, K | 1 |
| Tsuchihashi, K | 2 |
| Yamasaki, J | 1 |
| Kamenori, S | 1 |
| Shintani, S | 1 |
| Hirata, Y | 1 |
| Okazaki, S | 2 |
| Baba, E | 2 |
| Akashi, K | 2 |
| Mitsuishi, Y | 1 |
| Takahashi, F | 1 |
| Takahashi, K | 1 |
| Nagano, O | 2 |
| Blecic, S | 1 |
| Rynkowski, M | 1 |
| De Witte, O | 1 |
| Lefranc, F | 1 |
| Su, J | 1 |
| Liu, F | 1 |
| Xia, M | 1 |
| Xu, Y | 1 |
| Li, X | 1 |
| Kang, J | 1 |
| Li, Y | 1 |
| Sun, L | 1 |
| Thomas, AG | 1 |
| Sattler, R | 1 |
| Tendyke, K | 1 |
| Loiacono, KA | 1 |
| Hansen, H | 1 |
| Sahni, V | 1 |
| Hashizume, Y | 1 |
| Rojas, C | 1 |
| Slusher, BS | 1 |
| Yerokun, T | 1 |
| Winfield, LL | 1 |
| Ohmura, M | 1 |
| Ishikawa, M | 1 |
| Onishi, N | 1 |
| Wakimoto, H | 1 |
| Yoshikawa, M | 1 |
| Seishima, R | 1 |
| Iwasaki, Y | 1 |
| Morikawa, T | 1 |
| Abe, S | 1 |
| Takao, A | 1 |
| Shimizu, M | 1 |
| Masuko, T | 1 |
| Nagane, M | 1 |
| Furnari, FB | 1 |
| Akiyama, T | 1 |
| Suematsu, M | 1 |
| Sehm, T | 1 |
| Fan, Z | 1 |
| Ghoochani, A | 1 |
| Rauh, M | 1 |
| Engelhorn, T | 1 |
| Minakaki, G | 1 |
| Dörfler, A | 1 |
| Klucken, J | 1 |
| Eyüpoglu, IY | 1 |
| Ignarro, RS | 1 |
| Facchini, G | 1 |
| de Melo, DR | 1 |
| Pelizzaro-Rocha, KJ | 1 |
| Ferreira, CV | 1 |
| Castilho, RF | 1 |
| Rogerio, F | 1 |
| Nawashiro, H | 1 |
| Chung, WJ | 1 |
| Sontheimer, H | 4 |
| Robe, PA | 3 |
| Martin, DH | 1 |
| Nguyen-Khac, MT | 2 |
| Artesi, M | 1 |
| Deprez, M | 2 |
| Albert, A | 2 |
| Vanbelle, S | 1 |
| Califice, S | 1 |
| Bredel, M | 1 |
| Bours, V | 3 |
| Pham, AN | 1 |
| Blower, PE | 1 |
| Alvarado, O | 1 |
| Ravula, R | 1 |
| Gout, PW | 1 |
| Huang, Y | 1 |
| Buckingham, SC | 2 |
| Campbell, SL | 2 |
| Haas, BR | 1 |
| Montana, V | 1 |
| Robel, S | 1 |
| Ogunrinu, T | 1 |
| Bridges, RJ | 1 |
| Hermisson, M | 1 |
| Weller, M | 1 |
| Martin, D | 1 |
| Chariot, A | 1 |
| Lambert, F | 1 |
| Lechanteur, C | 1 |
| Jolois, O | 1 |
| Ernst-Gengoux, P | 1 |
| Rogister, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial Combining Sulfasalazine and Gamma Knife Radiosurgery for Recurrent Glioblastoma[NCT04205357] | Phase 1 | 24 participants (Actual) | Interventional | 2020-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sulfasalazine and Glial Cell Tumors
| Article | Year |
|---|---|
[Glutamate and malignant gliomas, from epilepsia to biological aggressiveness: therapeutic implications].
Topics: Benzodiazepines; Brain Neoplasms; Cell Death; Cell Movement; Cell Proliferation; Dizocilpine Maleate | 2013 |
2 trials available for sulfasalazine and Glial Cell Tumors
| Article | Year |
|---|---|
Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.
Topics: Adult; Disease Progression; Early Termination of Clinical Trials; Female; Glioma; Humans; Male; Midd | 2009 |
A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668].
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Brain Neoplasms; Disease | 2006 |
18 other studies available for sulfasalazine and Glial Cell Tumors
| Article | Year |
|---|---|
Chemical hybridization of sulfasalazine and dihydroartemisinin promotes brain tumor cell death.
Topics: Antineoplastic Agents; Artemisinins; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Glio | 2021 |
BTB domain and CNC homolog 1 promotes glioma invasion mainly through regulating extracellular matrix and increases ferroptosis sensitivity.
Topics: Basic-Leucine Zipper Transcription Factors; BTB-POZ Domain; Extracellular Matrix; Ferroptosis; Gliom | 2022 |
Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Brain Chemistry; | 2018 |
Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling.
Topics: Amino Acid Transport System y+; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prol | 2018 |
p62 participates in the inhibition of NF-κB signaling and apoptosis induced by sulfasalazine in human glioma U251 cells.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Autophagy; Cell Line, Tumor; Glioma; Humans; NF-kap | 2015 |
High-Throughput Assay Development for Cystine-Glutamate Antiporter (xc-) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells.
Topics: Amino Acid Transport System y+; Benzoates; Brain Neoplasms; Cell Line, Tumor; Cystine; Databases, Ch | 2015 |
Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Celecoxib; Cell Lin | 2015 |
The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-).
Topics: Amino Acid Transport System y+; Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Membrane; Ce | 2016 |
Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Topics: Amino Acid Transport System X-AG; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Glu | 2017 |
Idiopathic intracranial hypertension associated with sulphasalazine treatment.
Topics: Amino Acid Transport System y+; Anti-Inflammatory Agents, Non-Steroidal; Brain Neoplasms; Glioma; Hu | 2008 |
Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Li | 2009 |
Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferati | 2010 |
Glutamate release by primary brain tumors induces epileptic activity.
Topics: Amino Acid Transport System y+; Analysis of Variance; Animals; Brain Neoplasms; Cell Transplantation | 2011 |
Sulfasalazine for brain cancer fits.
Topics: Amino Acid Transport System y+; Animals; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Ep | 2012 |
Human glioma cells induce hyperexcitability in cortical networks.
Topics: Action Potentials; Animals; Brain; Brain Neoplasms; Disease Models, Animal; Electrophysiology; Femal | 2012 |
NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Cell Nu | 2003 |
Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas.
Topics: Bystander Effect; Cell Line, Tumor; Cell Survival; Ganciclovir; Genetic Therapy; Glioma; Humans; Sim | 2007 |